Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-07-2020 | Hemophilia | Review Article

Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India

Author: Tulika Seth

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2020

Abstract

The availability of clotting factor concentrates of both factor VIII and factor IX have improved hemophilia treatment to a great extent. Many more improvements like physiotherapy, and comprehensive care are needed to give better care. One important complication that occurs, but is often set aside is the development of inhibitors. When an inhibitor develops in a patient of severe hemophilia then the care becomes more difficult and expensive. Eradication of the inhibitor is possible by Immune tolerance induction (ITI), this paper explains some important essential factors and practical issues during my experience with ITI.

Wight J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–443PubMedCrossRef

Witmer C, Young G (2013) Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 4(1):59–72PubMedPubMedCentralCrossRef

Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P et al (2014) The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients. Indian J Hematol blood Transfus 30(4):356–363PubMedPubMedCentralCrossRef

Kar A, Phadnis S, Dharmarajan S, Nakade J (2014) Epidemiology & social costs of haemophilia in India. Indian J Med Res 140:19–31PubMedPubMedCentral

Ghosh K, Ghosh K (2016) Management of Haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 32(3):347–355PubMedCrossRef

Saxena K (2013) Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 4:49–56PubMedPubMedCentralCrossRef

Colowick AB, Bohn RL, Avorn J, Ewenstein BM (2000) Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 96(5):1698–1702PubMedCrossRef

Rocha P, Carvalho M, Lopes M, Araújo F (2015) Costs and utilization of treatment in patients with hemophilia. BMC Health Serv Res 15:484. https://doi.org/10.1186/s12913-015-1134-3 PubMedPubMedCentralCrossRef

Elisa Mancuso M, Cannavo A (2015) Immune tolerance induction in hemophilia. Clin Investig 5:321–335CrossRef

10.

Valentino LA, Kempton CL, Kruse-Jarres R, Mathew P, Meeks SL, Reiss UM (2015) US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia 21:559–567PubMedCrossRef

11.

Miller CH (2018) Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review. Haemophilia 24(2):186–197PubMedPubMedCentralCrossRef

12.

Adcock DM, Favaloro EJ (2015) Pearls and pitfalls in factor inhibitor assays. Int Jnl Lab Hem 37(1):52–60CrossRef

13.

Kempton CL, Meeks SL (2014) Toward optimal therapy for inhibitors in hemophilia. Hematol Am Soc Hematol Educ Program 2014:364–371CrossRef

14.

Valentino LA, Allen G, Gill JC, Hurlet A, Konkle BA, Leissinger CA et al (2013) Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia 19(3):e151–e166PubMedCrossRef

15.

Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G et al (2017) Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 377(9):809–818PubMedCrossRef

16.

Sherman A, Biswas M, Herzog RW (2017) Innovative approaches for immune tolerance to factor VIII in the treatment of Hemophilia A. Front Immunol 8:1604. https://doi.org/10.3389/fimmu.2017.01604 PubMedPubMedCentralCrossRef

17.

Mauz-Korholz C, Korholz D, Gobel U (1997) Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Thromb Haemost 78:959PubMedCrossRef

18.

Mauser-Bunschoten EP, Karel Nieuwenhuis H, Roosendaal G, Marijke van den Berg G (1995) Low-dose immune tolerance induction in Hemophilia A patients with inhibitors. Blood 86(3):983–988PubMedCrossRef

19.

Kavakli UK, Baytan B, Kazanci E, Sayli TY, Oren H, Celkan T, Gurse T (2008) Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. Haemophilia 14:315–322PubMedCrossRef

20.

Berntorp E, Astermark J, Carlborg E (2000) Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica 85(10):48–50PubMed

21.

Hay CRM, DiMichele DM (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119(6):1335–1344PubMedCrossRef

22.

Malec LM, Journeycake J, Ragni MV (2016) Extended half-life factor VIII for immune tolerance induction in haemophilia. Haemophilia 22(6):e552–e554PubMedCrossRef

23.

Brackmann H-H, White GC 2nd, Berntorp E, Andersen T, Escuriola-Ettingshausen C (2018) Immune tolerance induction: what have we learned over time? Haemophilia 24(3):3–14PubMedCrossRef

24.

Escuriola Ettingshausen C, Kreuz W (2013) The immune tolerance induction (ITI) dose debate: does the International ITI study provide a clearer picture? Haemophilia 19(1):12–17PubMedCrossRef

25.

Minno GD (2014) Predictors of ITI success according to evidence from literature data. Haemophilia 20(6):27–43PubMedCrossRef

26.

Jimenez-Yuste V, Oldenburg J, Rangarajan S, Peiro-Jordan R, Santagostino E (2016) Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. Haemophilia 22(6):859–865PubMedCrossRef

27.

Barnes C, Brown SA, Curtin J, Dunkley S (2014) When is enough… enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors. Haemophilia 20:e275–e279PubMedCrossRef

Title: Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India
Author: Tulika Seth
Publication date: 01-07-2020
Publisher: Springer India
Keyword: Hemophilia
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 3/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-019-01218-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Autoimmune Hemolytic Anemia as Presenting Manifestation of Multiple Myeloma

Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India

The Dilemma Between Autoimmune Trombocytopenia and Celiac Disease

Efficacy of Dichlorophenolindophenol (DCIP) as Screening Test for Hb E: Revisited

FLAER Based Assay According to Newer Guidelines Increases Sensitivity of PNH Clone Detection

Keynote webinar | Spotlight on antibody–drug conjugates in cancer